Arena Pharmaceuticals (NASDAQ:ARNA) reported earnings per share (EPS) for the quarter. During the same quarter in the previous year, the company posted ($0.09) earnings per share. The company’s revenue for the quarter was up 186.9% on a year-over-year basis. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) net profit margin is -24.00%and weekly performance is -0.58%.On last trading day company shares ended up $6.84. Analysts mean target price for the company is $8.06. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) distance from 50-day simple moving average (SMA50) is 5.21%.
MannKind Corporation (NASDAQ:MNKD) reported financial results for the first quarter ended March 31, 2014. For the first quarter of 2014, total operating expenses were $41.4 million, compared to $36.4 million for the first quarter of 2013, an increase of $5.0 million. Research and development (R&D) expenses were $26.2 million for the first quarter of 2014, compared to $26.4 million for the corresponding quarter in 2013, a decrease of $0.2 million. MannKind Corporation (NASDAQ:MNKD) shares advanced 1.77% in last trading session and ended the day on $6.33. MNKD return on assets is -78.70%.MannKind Corporation (NASDAQ:MNKD) quarterly performance is 11.25%
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) reported financial results for the quarter ended March 31, 2014. Total revenue was $2.4 million for the three months ended March 31, 2014, compared to $1.5 million for the same period in 2013. Total operating expenses were $12.4 million compared to $8.1 million. Inovio Pharmaceuticals Inc (NYSEMKT: INO) shares moved up 0.46% in last trading session and was closed at $2.17, while trading in range of $1.87 – $2.22. Inovio Pharmaceuticals Inc (NYSEMKT: INO) year to date (YTD) performance is -25.17%.
An investment community with a special focus on updating investors with recent news on the U.S. stock market about the small and penny stocks, issues news alert on Gilead Sciences, Inc.(NASDAQ:GILD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA).Gilead Sciences, Inc. (NASDAQ:GILD) ended the last trading day at $80.35. Company weekly volatility is calculated as 2.45% and price to cash ratio as 17.99. Gilead Sciences, Inc. (NASDAQ:GILD) showed a positive weekly performance of 0.65%
Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Chelsea Therapeutics International, Ltd (NASDAQ: CHTP) by the private equity firm H. Lundbeck A/S. On May 8, 2014, the two companies announced the signing of a definitive merger agreement pursuant to which Lundbeck will commence a tender offer for all outstanding shares of Chelsea Therapeutics. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) weekly performance is 28.65%.On last trading day company shares ended up $6.60. Analysts mean target price for the company is $9.50. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) distance from 50-day simple moving average (SMA50) is 21.39%.